UK Biotech's Gel Tech Breaks into Middle East, Aims to End Cold Chain

NEWCASTLE, England – April 15, 2026 – British biotech innovator Atelerix has forged a major strategic partnership with Saudi Arabia's JH Health Ltd, a move set to introduce its revolutionary cell preservation technology to the Middle East and challenge the dominance of costly cold chain logistics in the life sciences sector.

The agreement grants JH Health exclusive rights to distribute Atelerix's pioneering hydrogel solutions across the region, establishing a critical foothold in one of the world's fastest-growing healthcare markets. This collaboration goes beyond simple distribution, signaling plans for regional manufacturing and the development of new biobanking infrastructure, positioning both companies at the forefront of the Middle East's scientific ambitions.

A Technological Thaw in Biotech Logistics

At the heart of the partnership is Atelerix's proprietary hydrogel technology, a game-changing approach to preserving and transporting sensitive biological materials. For decades, the industry has relied on cryopreservation and a complex, energy-intensive 'cold chain' of freezers and specialized couriers to ship cells and tissues. This process is not only expensive but often results in significant sample degradation, with post-thaw viability rates sometimes dropping to between 70-80%.

Atelerix's solution, inspired by the natural hibernation mechanisms of hedgehogs, bypasses these challenges entirely. By encapsulating cells and tissues within a protective, soft hydrogel matrix, the technology stabilizes membrane integrity and preserves biological function at ambient temperatures for up to two weeks. Research demonstrates that this method can maintain cell viability above 90%, a significant improvement that ensures higher quality samples arrive at labs for diagnostics and research.

This innovation promises to democratize access to advanced biomedical tools. By eliminating the need for a cold chain, high-value biologicals like patient-derived cells, organoids, and advanced 3D tissue models can be shipped using standard couriers, drastically reducing costs and logistical complexity. The company has already validated this approach through partnerships with firms like Cherry Biotech for shipping organoid models and Labskin for transporting in vitro skin models, proving its technology can maintain sample integrity over long distances.

Fueling a Regional Life Science Revolution

The timing of Atelerix's entry into the Middle East is no coincidence. The region, particularly Saudi Arabia, is in the midst of a profound economic and scientific transformation driven by ambitious government initiatives like Saudi Vision 2030. This national strategy aims to diversify the economy away from oil, with biotechnology identified as a key pillar for future growth.

Market projections underscore the scale of this opportunity. The Middle East's life science tools market is forecast to surge from $2.4 billion in 2024 to nearly $4.3 billion by 2033, with Saudi Arabia leading the charge. This growth is fueled by massive government investment in healthcare infrastructure, genomics, and biomanufacturing, outlined in the Kingdom's National Biotechnology Strategy which aims to contribute over $34 billion to the non-oil GDP by 2040.

In this context, JH Health is more than a distributor; it is a strategic enabler. The Saudi firm will provide crucial financial support and local expertise to establish regional manufacturing capabilities for the hydrogel technology. This localization is key to meeting the surging demand and aligns with Vision 2030's goal of building a self-sufficient, high-tech domestic industry. JH Health's deep regional networks are essential for navigating the market and securing a competitive advantage.

From Lab Bench to Patient Bedside

The ultimate impact of this partnership extends far beyond corporate strategy, promising tangible benefits for patients and researchers across the Middle East. The ability to reliably transport patient-derived samples without degradation is critical for advancing clinical diagnostics, especially for managing the region's rising prevalence of chronic diseases like cancer and diabetes.

Furthermore, the collaboration will support the development of a new regional biobank. Biobanking is a cornerstone of modern medical research, providing the raw materials for genomic studies, drug discovery, and the development of personalized medicine. The Saudi biobanking market is already on a steep growth trajectory, projected to exceed $740 million by 2034. By providing a more efficient method for collecting and storing samples, the Atelerix-JH Health partnership can accelerate this growth and strengthen the region's research infrastructure.

"By partnering with JH Health, we gain access to the deep market expertise and local support needed to establish our operations in the Middle East," said Alastair Carrington, CEO of Atelerix. "Their strategic investment will enable us to build out our local manufacturing capabilities, ensuring we are equipped to deliver the future of biological transport logistics and meet the needs of the rapidly growing life science market in the region. This partnership is an integral next step in our strategy to bring our advanced cell preservation solutions to customers, worldwide."

Navigating the Path to Market

Before these benefits can be realized, the technology must clear the rigorous regulatory hurdles of the Saudi Food and Drug Authority (SFDA). The SFDA is known for its stringent evaluation process, requiring foreign manufacturers to obtain a Medical Device Marketing Authorization (MDMA) for any new products. This involves appointing a local Authorized Representative and submitting a comprehensive technical file that proves the device's safety and performance.

The approval process can be lengthy, often taking three to six months or more, and requires deep familiarity with local regulations. This is where JH Health's role as a local partner becomes invaluable. The Saudi company will lead the regulatory approval efforts, leveraging its in-country expertise to navigate the SFDA's requirements and expedite market access for Atelerix's technology.

Mohammed Al Jumah, CEO of JH Health, expressed his optimism for the collaboration's potential. "We are delighted to establish a strategic partnership with Atelerix to bring advanced biosample preservation technologies to the Middle East. By combining Atelerix’s pioneering solutions with our regional expertise, this collaboration enhances access to advanced tools that support biomedical research, accelerate scientific discovery, and strengthen clinical development across the region, ultimately improving healthcare outcomes."